Iatrogenic Effects of COX-2 Inhibitors in the US Population

  title={Iatrogenic Effects of COX-2 Inhibitors in the US Population},
  author={Rhema Vaithianathan and P. M. Hockey and T. J. Moore and D. Bates},
  journal={Drug Safety},
  • Rhema Vaithianathan, P. M. Hockey, +1 author D. Bates
  • Published 2009
  • Medicine
  • Drug Safety
  • AbstractBackground: Selective cyclo-oxygenase 2 inhibitors (‘coxibs’) have been demonstrated to increase cardiovascular risk, but the cumulative burden of adverse effects in the US population is uncertain. Objective: To quantify cardiovascular and gastrointestinal (GI) haemorrhage disease burden from coxibs and traditional ‘non-selective’ non-steroidal anti-inflammatory drugs (t-NSAIDs) in the US population. Design, setting and participants: Adult respondents from the 1999–2003 Medical… CONTINUE READING
    26 Citations
    Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.
    • S. Harirforoosh, Waheed Asghar, F. Jamali
    • Medicine
    • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
    • 2013
    • 301
    Cyclooxygenase Inhibition and P 2 Y 12 Antagonism
    • 2
    Prostanoids and NSAIDs in Cardiovascular Biology and Disease
    • 12
    “Safe and Effective When Used As Directed”: The Case of Chronic Use of Opioid Analgesics
    • 49
    • PDF


    Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    • 2,360
    • PDF